

BerGenBio and Oncoinvent – Last day of trading in the shares of Oncoinvent

Reference is made to the joint stock exchange announcement made on 24 October 2025 by BerGenBio ASA and Oncoinvent ASA ("**Oncoinvent**") regarding key dates for completion of the combination of the two companies through a statutory triangular merger (the "**Merger**"). Reference is further made to the stock exchange announcement made on 28 October 2025 regarding the approval and publication of the prospectus (the "**Prospectus**") prepared in connection with the Merger and the contemplated rights issue in the combined company.

The last day of trading in the shares of Oncoinvent on Euronext Growth Oslo will be today, 29 October 2025.

For further details on the timeline for completion of the Merger, please see the announcements mentioned above and the Prospectus.

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. One Phase 1 trial and one Phase 1/2a trial have been completed and one randomized Phase 2 trial is currently ongoing in the US, UK and Europe. Early clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. The Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext Growth Oslo.

Forward-looking statement:

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Oncoinvent's plans, estimates, or expectations will be achieved. These forward-looking statements represent Oncoinvent's expectations as of the date of this press release, and Oncoinvent disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers.